OnKure Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
OnKure Therapeutics (Nasdaq: OKUR) announced that President and CEO Nicholas Saccomano, Ph.D. will present and hold one-on-one investor meetings at three investor conferences in November–December 2025.
Scheduled appearances: a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on Nov 10, 2025 at 4:00 p.m. ET; a corporate presentation at the Stifel Healthcare Conference in New York on Nov 12, 2025 at 4:00 p.m. ET; and a fireside chat at the Evercore Healthcare Conference in Miami on Dec 3, 2025 at 12:30 p.m. ET. Live audio webcasts will be available for each event and replays will be posted on the company website for 30 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction – OKUR
In the Nov 5 session, OKUR declined 3.23%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.7% during that session. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences:
- A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link.
- A corporate presentation at the Stifel Healthcare Conference, in New York on November 12, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link.
- A fireside chat at the Evercore Healthcare Conference, in Miami on December 3, 2025, at 12:30 p.m. ET. A live audio webcast will be available through this link.
Following the events, replays will be available on the OnKure website (click here) for 30 days.
About OnKure Therapeutics
OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic or pathologically activated PI3Kα and has multiple programs designed to enable best-in-class targeting of this key disease creating gene.
For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.
Contact:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
